In this issue:
- Clinical impact of COVID-19 on cancer patients treated with ICIs
- Preliminary NCCN recommendations for COVID-19 vaccination
- Pretreatment BMI and outcomes in cancer patients treated with ICIs
- Low-dose pembrolizumab and nivolumab for relapsed/refractory classical HL
- Long-term survival in relapsed/refractory ALL treated with blinatumomab
- AFM13 + pembrolizumab in relapsed/refractory HL
- Pathophysiology and management of CAR T-cell therapy toxicities
- Immune reconstitution and infections following axi-cel for large B-cell lymphoma
- Second CD19-targeted CAR T-cell infusions for refractory B-cell malignancies
- Ide-cel in relapsed/refractory myeloma
Please login below to download this issue (PDF)